{"id":810085,"date":"2025-02-06T15:24:08","date_gmt":"2025-02-06T20:24:08","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/gsk-investors-have-opportunity-to-lead-gsk-plc-securities-fraud-lawsuit\/"},"modified":"2025-02-06T15:24:08","modified_gmt":"2025-02-06T20:24:08","slug":"gsk-investors-have-opportunity-to-lead-gsk-plc-securities-fraud-lawsuit","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/gsk-investors-have-opportunity-to-lead-gsk-plc-securities-fraud-lawsuit\/","title":{"rendered":"GSK Investors Have Opportunity to Lead GSK plc Securities Fraud Lawsuit"},"content":{"rendered":"
\n

PR Newswire<\/p>\n<\/p><\/div>\n

\n

\n
\n NEW YORK<\/span>
\n <\/span>, Feb. 6, 2025<\/span><\/span> \/PRNewswire\/ —<\/p>\n

\n

\n
\n \"Rosen
\n <\/a>\n <\/p>\n<\/p><\/div>\n

Why: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of American Depositary Receipts (“ADRs”) of GSK plc (NYSE: GSK) between February 5, 2020<\/span> and August 14, 2022<\/span>, both dates inclusive (the “Class Period”). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court\u00a0no later than April 7, 2025<\/span>.<\/p>\n

So what: If you purchased GSK ADRs\u00a0during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.<\/p>\n

What to do next: To join the GSK class action, go to\u00a0 https:\/\/rosenlegal.com\/submit-form\/?case_id=34609<\/a> or call Phillip Kim, Esq.<\/span> toll-free at 866-767-3653 or email case@rosenlegal.com<\/a> for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than April 7, 2025<\/span>. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.<\/p>\n

Why Rosen Law: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm achieved the largest ever securities class action settlement against a Chinese Company at the time. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million<\/span> for investors. In 2020, founding partner Laurence Rosen<\/span> was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.<\/p>\n

Details of the case: The complaint alleges<\/span> that, throughout the Class Period, defendants represented to investors that GSK removed Zantac, a treatment for heartburn and acid reflux, from the market “[b]ased on information available at the time and correspondence with regulators,” and that GSK was “continuing with investigations into the potential source of NDMA, [a cancer-causing poison].” Defendants also assured investors that “GSK, the FDA [U.S. Food and Drug Administration], and the EMA [European Medicines Agency] have all independently concluded that there is no evidence of a causal\u00a0 association between ranitidine therapy and the development of cancer in patients,” findings that were “consistent with other ranitidine data published prior to 2019.” Finally, defendants claimed that they could not “quantify or reliably estimate the liability” GSK could face from Zantac-related legal proceedings.<\/p>\n

These representations were materially false or misleading. In truth, GSK was fully aware of the source of NDMA and had been for nearly 40 years before withdrawing Zantac from the market. Furthermore, defendants’ representations about their ability to “quantify or reliably estimate the liability” deceived investors, who did not know that GSK had for decades concealed an internal study that implicated GSK’s liability to Zantac users. When the true details entered the market, the lawsuit claims that investors suffered damages.<\/p>\n

To join the GSK class action, go to https:\/\/rosenlegal.com\/submit-form\/?case_id=34609<\/a> or call Phillip Kim, Esq.<\/span> toll-free at 866-767-3653 or email case@rosenlegal.com<\/a> for information on the class action. A class action lawsuit has already been filed.<\/p>\n

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.<\/p>\n

Follow us for updates on LinkedIn: https:\/\/www.linkedin.com\/company\/the-rosen-law-firm<\/a>, on Twitter: https:\/\/twitter.com\/rosen_firm<\/a> or on Facebook: https:\/\/www.facebook.com\/rosenlawfirm\/<\/a>.<\/p>\n

Attorney Advertising. Prior results do not guarantee a similar outcome.<\/p>\n

Contact Information:<\/p>\n

\u00a0\u00a0\u00a0\u00a0\u00a0 Laurence Rosen, Esq.<\/span>
\u00a0\u00a0\u00a0\u00a0\u00a0 Phillip Kim, Esq.<\/span>
\u00a0\u00a0\u00a0\u00a0\u00a0 The Rosen Law Firm, P.A.
\u00a0\u00a0\u00a0\u00a0\u00a0 275 Madison Avenue, 40th Floor
\u00a0\u00a0\u00a0\u00a0\u00a0 New York, NY<\/span> 10016
\u00a0\u00a0\u00a0\u00a0\u00a0 Tel: (212) 686-1060
\u00a0\u00a0\u00a0\u00a0\u00a0 Toll Free: (866) 767-3653
\u00a0\u00a0\u00a0\u00a0\u00a0 Fax: (212) 202-3827
\u00a0\u00a0\u00a0\u00a0\u00a0 case@rosenlegal.com<\/a>
\u00a0\u00a0\u00a0\u00a0\u00a0 www.rosenlegal.com<\/a><\/p>\n

\n \"Cision\" View original content to download multimedia:https:\/\/www.prnewswire.com\/news-releases\/gsk-investors-have-opportunity-to-lead-gsk-plc-securities-fraud-lawsuit-302370448.html<\/a><\/p>\n

SOURCE THE ROSEN LAW FIRM, P. A.<\/p>\n<\/p><\/div>\n

\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

PR Newswire NEW YORK , Feb. 6, 2025 \/PRNewswire\/ — Why: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of American Depositary Receipts (“ADRs”) of GSK plc (NYSE: GSK) between February 5, 2020 and August 14, 2022, both dates inclusive (the “Class Period”). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court\u00a0no later than April 7, 2025. So what: If you purchased GSK ADRs\u00a0during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. What to do next: To join the … <\/p>\n

Continue reading “GSK Investors Have Opportunity to Lead GSK plc Securities Fraud Lawsuit”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-810085","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nGSK Investors Have Opportunity to Lead GSK plc Securities Fraud Lawsuit - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/gsk-investors-have-opportunity-to-lead-gsk-plc-securities-fraud-lawsuit\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"GSK Investors Have Opportunity to Lead GSK plc Securities Fraud Lawsuit - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PR Newswire NEW YORK , Feb. 6, 2025 \/PRNewswire\/ — Why: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of American Depositary Receipts (“ADRs”) of GSK plc (NYSE: GSK) between February 5, 2020 and August 14, 2022, both dates inclusive (the “Class Period”). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court\u00a0no later than April 7, 2025. So what: If you purchased GSK ADRs\u00a0during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. What to do next: To join the … Continue reading "GSK Investors Have Opportunity to Lead GSK plc Securities Fraud Lawsuit"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/gsk-investors-have-opportunity-to-lead-gsk-plc-securities-fraud-lawsuit\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-02-06T20:24:08+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mma.prnewswire.com\/media\/405060\/Rosen_Law_Logo.jpg\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/gsk-investors-have-opportunity-to-lead-gsk-plc-securities-fraud-lawsuit\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/gsk-investors-have-opportunity-to-lead-gsk-plc-securities-fraud-lawsuit\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"GSK Investors Have Opportunity to Lead GSK plc Securities Fraud Lawsuit\",\"datePublished\":\"2025-02-06T20:24:08+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/gsk-investors-have-opportunity-to-lead-gsk-plc-securities-fraud-lawsuit\\\/\"},\"wordCount\":756,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/gsk-investors-have-opportunity-to-lead-gsk-plc-securities-fraud-lawsuit\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/405060\\\/Rosen_Law_Logo.jpg\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/gsk-investors-have-opportunity-to-lead-gsk-plc-securities-fraud-lawsuit\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/gsk-investors-have-opportunity-to-lead-gsk-plc-securities-fraud-lawsuit\\\/\",\"name\":\"GSK Investors Have Opportunity to Lead GSK plc Securities Fraud Lawsuit - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/gsk-investors-have-opportunity-to-lead-gsk-plc-securities-fraud-lawsuit\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/gsk-investors-have-opportunity-to-lead-gsk-plc-securities-fraud-lawsuit\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/405060\\\/Rosen_Law_Logo.jpg\",\"datePublished\":\"2025-02-06T20:24:08+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/gsk-investors-have-opportunity-to-lead-gsk-plc-securities-fraud-lawsuit\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/gsk-investors-have-opportunity-to-lead-gsk-plc-securities-fraud-lawsuit\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/gsk-investors-have-opportunity-to-lead-gsk-plc-securities-fraud-lawsuit\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/405060\\\/Rosen_Law_Logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/405060\\\/Rosen_Law_Logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/gsk-investors-have-opportunity-to-lead-gsk-plc-securities-fraud-lawsuit\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"GSK Investors Have Opportunity to Lead GSK plc Securities Fraud Lawsuit\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"GSK Investors Have Opportunity to Lead GSK plc Securities Fraud Lawsuit - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/gsk-investors-have-opportunity-to-lead-gsk-plc-securities-fraud-lawsuit\/","og_locale":"en_US","og_type":"article","og_title":"GSK Investors Have Opportunity to Lead GSK plc Securities Fraud Lawsuit - Market Newsdesk","og_description":"PR Newswire NEW YORK , Feb. 6, 2025 \/PRNewswire\/ — Why: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of American Depositary Receipts (“ADRs”) of GSK plc (NYSE: GSK) between February 5, 2020 and August 14, 2022, both dates inclusive (the “Class Period”). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court\u00a0no later than April 7, 2025. So what: If you purchased GSK ADRs\u00a0during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. What to do next: To join the … Continue reading \"GSK Investors Have Opportunity to Lead GSK plc Securities Fraud Lawsuit\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/gsk-investors-have-opportunity-to-lead-gsk-plc-securities-fraud-lawsuit\/","og_site_name":"Market Newsdesk","article_published_time":"2025-02-06T20:24:08+00:00","og_image":[{"url":"https:\/\/mma.prnewswire.com\/media\/405060\/Rosen_Law_Logo.jpg","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/gsk-investors-have-opportunity-to-lead-gsk-plc-securities-fraud-lawsuit\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/gsk-investors-have-opportunity-to-lead-gsk-plc-securities-fraud-lawsuit\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"GSK Investors Have Opportunity to Lead GSK plc Securities Fraud Lawsuit","datePublished":"2025-02-06T20:24:08+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/gsk-investors-have-opportunity-to-lead-gsk-plc-securities-fraud-lawsuit\/"},"wordCount":756,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/gsk-investors-have-opportunity-to-lead-gsk-plc-securities-fraud-lawsuit\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/405060\/Rosen_Law_Logo.jpg","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/gsk-investors-have-opportunity-to-lead-gsk-plc-securities-fraud-lawsuit\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/gsk-investors-have-opportunity-to-lead-gsk-plc-securities-fraud-lawsuit\/","name":"GSK Investors Have Opportunity to Lead GSK plc Securities Fraud Lawsuit - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/gsk-investors-have-opportunity-to-lead-gsk-plc-securities-fraud-lawsuit\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/gsk-investors-have-opportunity-to-lead-gsk-plc-securities-fraud-lawsuit\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/405060\/Rosen_Law_Logo.jpg","datePublished":"2025-02-06T20:24:08+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/gsk-investors-have-opportunity-to-lead-gsk-plc-securities-fraud-lawsuit\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/gsk-investors-have-opportunity-to-lead-gsk-plc-securities-fraud-lawsuit\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/gsk-investors-have-opportunity-to-lead-gsk-plc-securities-fraud-lawsuit\/#primaryimage","url":"https:\/\/mma.prnewswire.com\/media\/405060\/Rosen_Law_Logo.jpg","contentUrl":"https:\/\/mma.prnewswire.com\/media\/405060\/Rosen_Law_Logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/gsk-investors-have-opportunity-to-lead-gsk-plc-securities-fraud-lawsuit\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"GSK Investors Have Opportunity to Lead GSK plc Securities Fraud Lawsuit"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/810085","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=810085"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/810085\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=810085"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=810085"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=810085"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}